Otros idiomas FUSN PHAR

Acciones

FUSN

CA36118A1003

Diferido Nasdaq Otros sitios de cotización 22:00:00 03/06/2024			Varia. Cinco días.	Varia. 1 de enero.
21,55 ^USD	+0,14 %		0,00 %	+124,25 %

04/06	Fusion Pharmaceuticals dice que se ha completado la adquisición por 2.400 millones de dólares por parte de una unidad de AstraZeneca	MT
04/06	AstraZeneca AB completó la adquisición de Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) a un grupo de accionistas.	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete	04/06
Acquisition of Fusion Pharmaceuticals Completed	04/06
Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index	04/06
AstraZeneca AB completed the acquisition of Fusion Pharmaceuticals Inc. from a group of shareholders.	04/06
Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Composite Index	03/06
Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal	31/05
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement	31/05
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement	31/05
Fusion Pharmaceuticals Shareholders Approve AstraZeneca Deal	29/05
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca	29/05
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	09/05
Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	09/05
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN	09/05
Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates	07/05
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order	25/04
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order	25/04
Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	09/04
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024	09/04
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN	27/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas FUSN PHAR

Acciones

FUSN

CA36118A1003

Otros idiomas

Filtros